IL17F
ENSG00000112116
Target class
Secreted protein
Chromosome
6
Approved drugs
1
Clinical candidates (approved and in development)
2
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 2
- Chemical probe available
- No
- Target name
- IL17F
- Gene name
- Interleukin 17F
- Gene symbol
- IL17F
- Protein name
- Interleukin-17F (IL-17F) (Cytokine ML-1)
- IL-17F
- ML-1
- ML1
- Gene biotype
- Protein coding
- Gene family
- Interleukins
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 1
- Highest tissue expression
- 1.19
- Tissue specificity (Gini)
- 0.977
- Tissue specificity (tau)
- 0.998
- KEGG gene identifiers
- hsa:112744
- Protein interaction confidence
- 0.846743
- Protein interaction partners
- 35
- R-HSA-448424
- R-HSA-6785807
- R-HSA-9705671
- End position
- 52245689
- Start position
- 52236681
- Chromosome
- 6
- Strand
- Reverse
- Secreted .
- Tissue specificity (tau)
- 0.998097
- Expression inequality (Gini)
- 0.977241
Expression in transcripts per million
- Testis
- 1.19
- Brain - Cerebellum
- 0.09
- Brain - Nucleus accumbens (basal ganglia)
- 0.03
- Brain - Hypothalamus
- 0
- Cells - EBV-transformed lymphocytes
- 0
Expression in transcripts per million
- Testis1.19
- Brain - Cerebellum0.09
- Brain - Nucleus accumbens (basal ganglia)0.03
- Brain - Hypothalamus0
- Cells - EBV-transformed lymphocytes0
- Artery - Coronary0
- Spleen0
- Liver0
- Minor Salivary Gland0
- Fallopian Tube0
- Heart - Atrial Appendage0
- Cervix - Endocervix0
- Kidney - Medulla0
- Adipose - Subcutaneous0
- Brain - Cortex0
- Brain - Amygdala0
- Esophagus - Muscularis0
- Brain - Frontal Cortex (BA9)0
- Heart - Left Ventricle0
- Kidney - Cortex0
- Skin - Not Sun Exposed (Suprapubic)0
- Esophagus - Mucosa0
- Breast - Mammary Tissue0
- Bladder0
- Artery - Tibial0
And 29 more, listed on the interactive page.
- GO:0001819
- GO:0016525
- GO:0017015
- GO:0032645
- GO:0032663
- GO:0032675
- GO:0032677
- GO:0032755
- GO:0032761
- GO:0051216
- GO:0097400
- GO:2000340
Cellular components
- GO:0005576
- GO:0005125
- GO:0005515
- GO:0019955
- GO:0042803
Related records
Trials (66)
- A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants
- A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
- A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)
- A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
- A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis
- A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
- A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis
- A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis
- A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer Participants
- A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects
- A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants
- A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis
- A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis
- A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
- A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Drugs (2)
- Bimekizumab Interleukin-17F inhibitor
- M-1095 Interleukin-17F inhibitor